C4 Therapeutics Inc is trading 5.1% up at $4.10 in after-hours trading following the presentation of positive Phase 1 data for its CELMoD degrader, cemsidomide.
- The data, presented at the EHA Congress, showed a 53% overall response rate and a favorable safety profile in patients with relapsed/refractory multiple myeloma.
- The stock is extending a strong regular session move, bolstered by a supportive backdrop as broader indices trade modestly higher.